Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4562 ARTÍCULOS , VIENDO DEL 1696 AL 1710

Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review

Sahu JK, Mishra AK.

Curr Mol Pharmacol. 2018;11(4):270-278. doi: 10.2174/1874467211666180821101158.

[Social costs of diseases: How relevant are they for economic evaluations?]

Mareque M, Oliva Moreno J.

Rev Esp Salud Publica. 2018 Aug 22;92:e201808051.

Parkinson's disease pathogenesis, evolution and alternative pathways: A review

Alexoudi A, Alexoudi I, Gatzonis S.

Rev Neurol (Paris). 2018 Dec;174(10):699-704. doi: 10.1016/j.neurol.2017.12.003. Epub 2018 Aug 18.

Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease

Telkes I, Viswanathan A, Jimenez-Shahed J, Abosch A, Ozturk M, Gupte A, Jankovic J, Ince NF.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8567-E8576. doi: 10.1073/pnas.1810589115. Epub 2018 Aug 21.

What influences placebo and nocebo responses in Parkinson's disease?

Witek N, Stebbins GT, Goetz CG.

Mov Disord. 2018 Aug;33(8):1204-1212. doi: 10.1002/mds.27416. Epub 2018 Aug 22.

Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features

Ray Chaudhuri K, Poewe W, Brooks D.

Mov Disord. 2018 Jul;33(6):909-919. doi: 10.1002/mds.27386.

Serum 25-hydroxyvitamin D3 level may be associated with olfactory dysfunction in de novo Parkinson's disease

Kim JE, Oh E, Park J, Youn J, Kim JS, Jang W.

J Clin Neurosci. 2018 Nov;57:131-135. doi: 10.1016/j.jocn.2018.08.003. Epub 2018 Aug 19.

Repositioning Microtubule Stabilizing Drugs for Brain Disorders

Varidaki A, Hong Y, Coffey ET.

Front Cell Neurosci. 2018 Aug 8;12:226. doi: 10.3389/fncel.2018.00226. eCollection 2018.

Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease

Lim J, Bang Y, Choi HJ.

Arch Pharm Res. 2018 Oct;41(10):943-954. doi: 10.1007/s12272-018-1063-x. Epub 2018 Aug 22.

Can neuroimaging predict dementia in Parkinson's disease?

Lanskey JH, McColgan P, Schrag AE, Acosta-Cabronero J, Rees G, Morris HR, Weil RS.

Brain. 2018 Sep 1;141(9):2545-2560. doi: 10.1093/brain/awy211.

Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date

Boersema PJ, Melnik A, Hazenberg BPC, Rezeli M, Marko-Varga G, Kamiie J, Portelius E, Blennow K, Zubarev RA, Polymenidou M, Picotti P.

J Proteome Res. 2018 Dec 7;17(12):4072-4084. doi: 10.1021/acs.jproteome.8b00401. Epub 2018 Sep 28.

Turning Stability in Individuals With Parkinson Disease

Conradsson D, Paquette C, Franzén E.

J Neurol Phys Ther. 2018 Oct;42(4):241-247. doi: 10.1097/NPT.0000000000000242.

Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies

Gupta N, Shyamasundar S, Patnala R, Karthikeyan A, Arumugam TV, Ling EA, Dheen ST.

Expert Opin Ther Targets. 2018 Sep;22(9):765-781. doi: 10.1080/14728222.2018.1515917. Epub 2018 Sep 10.

Relevance of gutmicrobiota in cognition, behaviour and Alzheimer's disease

de J R De-Paula V, Forlenza AS, Forlenza OV.

Pharmacol Res. 2018 Oct;136:29-34. doi: 10.1016/j.phrs.2018.07.007. Epub 2018 Aug 20.

Sphingosine kinase 1/sphingosine-1-phosphate receptors dependent signalling in neurodegenerative diseases. The promising target for neuroprotection in Parkinson's disease

Motyl J, Strosznajder JB.

Pharmacol Rep. 2018 Oct;70(5):1010-1014. doi: 10.1016/j.pharep.2018.05.002. Epub 2018 Jun 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias